Work

Real-world outcomes and adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer (1103)

Year: 2023

Type: article

Study design: Observational Study

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2023.06.025

Authors: William Zammarrelli, Weining Ma, Kevin Espino, Effi Yeoshoua, Sarah Ehmann, Qin Zhou, Alexia Iasonos, Nadeem Abu-Rustum, Carol Aghajanian, Angela Green, Maria Rubinstein, Vicky Makker

Institutions: Memorial Sloan Kettering Cancer Center, NYU Langone Health

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4386948303

FWCI:

Cites:

Cited by:

Related to: 10